Personalized Medicine Decision-Making in a Virtual Clinical Setting

Status Completed

Clinical Trial Summary

Background: -How people respond to drugs depends in part on their genes. For some drugs, doctors can use an individuals genetic background to help in dosing the drug. Researchers want to know how doctors incorporate personalized or genomic medicine into clinical practice. Objective: -To study how physicians make personalized treatment decisions Eligibility: -Healthy adult primary care physicians who are internal (or family) medicine residents. Design: - Participants will complete a screening form. - Participants will put on a headset, called a head-mounted display, showing a virtual reality environment. - The environment will contain an exam room and the virtual patient. - After interacting with the virtual patient, participants will complete a series of survey measures. - Participation will last for about 60 minutes. The virtual patient interaction and follow-up questions will be audio taped.

Clinical Trial Description

This study will examine factors related to primary care physicians clinical decision-making. Using a virtual clinical interaction experiment, we aim to better understand physicians decision-making processes and to explore their communication behaviors toward patients in the clinical encounter. Physician participants will enter a virtual exam room where they will be asked to respond to a virtual patient, acting as her primary care physician in a follow-up visit to evaluate her for depression. Various aspects of physician communication in the virtual clinic and self-report measures related to decision-making will be analyzed. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02108041
Study type	Observational
Source	National Institutes of Health Clinical Center (CC)
Contact
Status	Completed
Phase
Completion date	October 8, 2020

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05003843` - BOLT: Study of the Indigo® Aspiration System When Used in Patients With Deep Vein Thrombosis	N/A
Recruiting	`NCT03937947` - Traumatic Brain Injury Associated Radiological DVT Incidence and Significance Study
Withdrawn	`NCT04136561` - Novel Strategy to Encourage Early Removal of Central Venous Catheters	N/A
Completed	`NCT03420625` - Blood Flow Stimulation in the Lower Limbs by Application of Different External Devices	N/A
Recruiting	`NCT02507180` - Safely Ruling Out Deep Vein Thrombosis in Pregnancy With the LEFt Clinical Decision Rule and D-Dimer
Completed	`NCT02555111` - Xarelto Versus no Treatment for the Prevention of Recurrent Thrombosis in Patients With Chronic Portal Vein Thrombosis.	Phase 3
Completed	`NCT01975090` - The SENTRY Clinical Study	N/A
Terminated	`NCT02469376` - Evaluation of a New Imagingtechnologie for Thrombosis	Phase 1
Completed	`NCT02037607` - Incidence of Venous Thromboembolism in Children Undergoing Elective Neurosurgical Procedures	N/A
Not yet recruiting	`NCT01357941` - Need for Antepartum Thromboprophylaxis in Pregnant Women With One Prior Episode of Venous Thromboembolism (VTE)	N/A
Completed	`NCT00773448` - Screening for Occult Malignancy in Patients With Idiopathic Venous Thromboembolism	N/A
Completed	`NCT00720915` - D-dimer to Select Patients With First Unprovoked Venous Thromboembolism Who Can Have Anticoagulants Stopped at 3 Months	N/A
Completed	`NCT00771303` - Ruling Out Pulmonary Embolism During Pregnancy:a Multicenter Outcome Study
Completed	`NCT00244725` - Odiparcil For The Prevention Of Venous Thromboembolism	Phase 2
Completed	`NCT00264277` - D-dimer to Establish Duration of Anticoagulation After Venous Thromboembolism	Phase 4
Completed	`NCT00365950` - 3 Months' Versus 6 Months' Anticoagulation in Patients With DVT and/or PE	Phase 4
Completed	`NCT00182403` - Fixed Dose Heparin Study	Phase 3
Completed	`NCT03682419` - Evaluation of Precision and Accuracy of INR Measurements in a Point of Care Device (OPTIMAL)	N/A
Not yet recruiting	`NCT04981327` - The API-CALF Study: Apixaban to Treat Calf Vein Thrombosis	Phase 3
Recruiting	`NCT03240120` - A Study of Dabigatran Etexilate as Primary Treatment of Malignancy Associated Venous Thromboembolism	Phase 3